Racivir

Presentations

Study 201
Racivir Demonstrates Activity in Patients Resistant to Lamivudine
Frontiers in Drug Development for Antiretroviral Therapies (HIV DART)
Cancun, Mexico
December 10-14, 2006

Study 201
Racivir Demonstrates Safety and Efficacy in Patients Harboring HIV with the M184V Mutation and <3 TAM
14th Conference on Retroviruses and Opportunistic Infections (CROI)
February 25-28, 2007

Study 201
Clonal Analysis of Samples from Virologic Responders Receiving Racivir in Study 201
16th International HIV Drug Resistance Workshop
St. Michael, Barbados
June 12-15, 2007

Publications

Herzmann C, Arasteh K. Murphy RL, Schulbin H, Kreckel P, Drauz D, Schinazi RF, Beard A, Cartee L, Otto MJ. Safety, Pharmacokinetics, and Efficacy of (+/–)-{Beta}-2’,3’-Dideoxy-5-Fluoro-3’-Thiacytidine with Efavirenz and Stavudine in Antiretroviral-Naïve Human Immunodeficiency Virus-Infected Patients. 2005. Antimicrobial Agents and Chemotherapy. Vol.49, No.7, 2828-2833.